Renovaro Inc
RENB0.260USD
+0.002+0.58%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
42.22MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Renovaro Inc Unternehmen
Renovaro Inc. specializes in cancer diagnostics and therapeutics powered by artificial intelligence (AI). The Company operates through two subsidiaries: Renovaro Biosciences, Inc. (Renovaro Biosciences) and Renovaro Cube. Renovaro Biosciences is a biotechnology company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed an AI platform that analyzes genetics using Explainable AI to provide earlier and more accurate cancer diagnosis. This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
Unternehmensinformationen
BörsenkürzelRENB
Name des UnternehmensRenovaro Inc
IPO-datumNov 18, 2014
CEOMr. David Weinstein
Anzahl der mitarbeiter25
WertpapierartOrdinary Share
GeschäftsjahresendeNov 18
Addresse2080 Century Park East,
StadtLOS ANGELES
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl90067
Telefon14539179840
Websitehttps://renovarobio.com/
BörsenkürzelRENB
IPO-datumNov 18, 2014
CEOMr. David Weinstein
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Maurice Van Tilburg
Mr. Maurice Van Tilburg
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President
Executive Vice President
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Maurice Van Tilburg
Mr. Maurice Van Tilburg
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President
Executive Vice President
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
PasecoApS
11.69%
RS Group ApS
7.29%
Gumrukcu (Serhat)
5.42%
BlackRock Institutional Trust Company, N.A.
2.95%
The Vanguard Group, Inc.
2.45%
Other
70.20%
Aktionäre
Aktionäre
Anteil
PasecoApS
11.69%
RS Group ApS
7.29%
Gumrukcu (Serhat)
5.42%
BlackRock Institutional Trust Company, N.A.
2.95%
The Vanguard Group, Inc.
2.45%
Other
70.20%
Aktionärstypen
Aktionäre
Anteil
Corporation
36.84%
Individual Investor
10.44%
Investment Advisor
8.61%
Investment Advisor/Hedge Fund
3.55%
Research Firm
0.41%
Hedge Fund
0.13%
Bank and Trust
0.07%
Pension Fund
0.04%
Other
39.92%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
157
103.42M
47.15%
+42.61M
2025Q1
161
103.48M
60.94%
+42.30M
2024Q4
155
103.71M
63.86%
+49.62M
2024Q3
149
51.49M
35.21%
-1.80M
2024Q2
151
51.88M
36.43%
+6.39M
2024Q1
154
44.98M
32.23%
+3.81M
2023Q4
151
44.01M
67.51%
+217.77K
2023Q3
146
41.12M
71.08%
+1.11M
2023Q2
147
41.48M
71.99%
+3.87M
2023Q1
143
36.45M
65.90%
-482.82K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
PasecoApS
12.62M
7.33%
+8.16M
+182.78%
Oct 17, 2024
RS Group ApS
13.60M
7.9%
+468.70K
+3.57%
Oct 17, 2024
Gumrukcu (Serhat)
12.53M
7.28%
--
--
Apr 10, 2025
BlackRock Institutional Trust Company, N.A.
6.81M
3.96%
+847.01K
+14.20%
Mar 31, 2025
The Vanguard Group, Inc.
5.66M
3.29%
-58.46K
-1.02%
Mar 31, 2025
William (Anderson Wittekind)
4.77M
2.77%
--
--
Apr 10, 2025
Geode Capital Management, L.L.C.
2.37M
1.38%
+35.02K
+1.50%
Mar 31, 2025
State Street Global Advisors (US)
2.00M
1.16%
-61.67K
-2.99%
Mar 31, 2025
Weinstein (David Hershel)
250.00K
0.15%
+250.00K
--
Oct 17, 2024
Weird Science LLC
840.32K
0.49%
--
--
Apr 10, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
iShares Russell 2000 ETF
Anteil0%
iShares Micro-Cap ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
